Rankings
▼
Calendar
BIIB Q3 2017 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena
BIIB
Biogen Inc.
$28B
Q3 2017 Earnings
Healthcare
Drug Manufacturers - General
Income Statement
Revenue
$3.1B
+4.1% YoY
Gross Profit
$2.7B
88.0% margin
Operating Income
$1.7B
53.7% margin
Net Income
$1.2B
39.8% margin
EPS (Diluted)
$5.79
QoQ Revenue Growth
-0.0%
Cash Flow
Operating Cash Flow
$1.6B
Free Cash Flow
$1.3B
Stock-Based Comp.
$30M
Balance Sheet
Total Assets
$23.1B
Total Liabilities
$10.2B
Stockholders' Equity
$12.9B
Cash & Equivalents
$1.5B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$3.1B
$3.0B
+4.1%
Gross Profit
$2.7B
$2.5B
+6.7%
Operating Income
$1.7B
$1.4B
+16.0%
Net Income
$1.2B
$1.0B
+18.7%
Revenue Segments
Hemophilia Products
$74M
100%
← FY 2017
All Quarters
Q4 2017 →